Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Get Free Report) has been given an average rating of “Moderate Buy” by the nine brokerages that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $143.44.
A number of equities research analysts have recently commented on the stock. Oppenheimer reiterated an “outperform” rating and issued a $143.00 target price (up from $134.00) on shares of Praxis Precision Medicines in a research report on Wednesday, September 4th. Guggenheim increased their price objective on shares of Praxis Precision Medicines from $155.00 to $170.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. HC Wainwright restated a “buy” rating and set a $120.00 target price on shares of Praxis Precision Medicines in a report on Tuesday, September 10th. Wedbush increased their price target on Praxis Precision Medicines from $40.00 to $48.00 and gave the company a “neutral” rating in a report on Wednesday, August 14th. Finally, Needham & Company LLC reissued a “buy” rating and set a $145.00 price objective on shares of Praxis Precision Medicines in a research note on Tuesday, September 3rd.
Get Our Latest Analysis on Praxis Precision Medicines
Hedge Funds Weigh In On Praxis Precision Medicines
Praxis Precision Medicines Trading Up 1.5 %
NASDAQ PRAX opened at $71.54 on Monday. Praxis Precision Medicines has a twelve month low of $13.01 and a twelve month high of $75.73. The stock has a 50-day moving average of $60.33 and a 200 day moving average of $52.51. The stock has a market capitalization of $1.22 billion, a price-to-earnings ratio of -4.51 and a beta of 2.73.
Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($1.74) EPS for the quarter, topping the consensus estimate of ($2.38) by $0.64. Praxis Precision Medicines had a negative return on equity of 61.47% and a negative net margin of 6,987.01%. The company had revenue of $0.36 million during the quarter, compared to analyst estimates of $1.44 million. Equities analysts predict that Praxis Precision Medicines will post -8.5 EPS for the current fiscal year.
Praxis Precision Medicines Company Profile
Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.
Featured Stories
- Five stocks we like better than Praxis Precision Medicines
- Quiet Period Expirations Explained
- Texas Roadhouse Stock Steering for New Highs This Year
- Best Stocks Under $10.00
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- What is a Bond Market Holiday? How to Invest and Trade
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Praxis Precision Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Praxis Precision Medicines and related companies with MarketBeat.com's FREE daily email newsletter.